RT Journal Article
T1 Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
A1 Castaño-Bonilla, Tamara
A1 Alonso-Dominguez, Juan M
A1 Barragan, Eva
A1 Rodriguez-Veiga, Rebeca
A1 Sargas, Claudia
A1 Gil, Cristina
A1 Chillon, Carmen
A1 Vidriales, Maria B
A1 Garcia, Raimundo
A1 Martinez-Lopez, Joaquin
A1 Ayala, Rosa
A1 Larrayoz, Maria J
A1 Anguita, Eduardo
A1 Cuello, Rebeca
A1 Cantalapiedra, Alberto
A1 Carrillo, Estrella
A1 Soria-Saldise, Elena
A1 Labrador, Jorge
A1 Recio, Isabel
A1 Algarra, Lorenzo
A1 Rodriguez-Medina, Carlos
A1 Bilbao-Syeiro, Cristina
A1 Lopez-Lopez, Juan A
A1 Serrano, Josefina
A1 De-Cabo, Erik
A1 Sayas, Maria J
A1 Olave, Maria T
A1 Sanchez-Garcia, Joaquin
A1 Mateos, Mamen
A1 Blas, Carlos
A1 Lopez-Lorenzo, Jose L
A1 Lainez-Gonzalez, Daniel
A1 Serrano, Juana
A1 Martinez-Cuadron, David
A1 Sanz, Miguel A
A1 Montesinos, Pau
K1 Acute myeloid leukaemia
K1 Molecular medicine
K1 Oncogenesis
K1 Prognostic markers
AB FLT3-ITD mutations are detected in approximately 25% of newly diagnosed adult acute myeloid leukemia (AML) patients and confer an adverse prognosis. The FLT3-ITD allelic ratio has clear prognostic value. Nevertheless, there are numerous manuscripts with contradictory results regarding the prognostic relevance of the length and insertion site (IS) of the FLT3-ITD fragment. We aimed to assess the prognostic impact of these variables on the complete remission (CR) rates, overall survival (OS) and relapse-free survival (RFS) of AML patients with FLT3-ITDmutations. We studied the FLT3-ITD length of 362 adult AML patients included in the PETHEMA AML registry. We tried to validate the thresholds of ITD length previously published (i.e., 39 bp and 70 bp) in intensively treated AML patients (n = 161). We also analyzed the mutational profile of 118 FLT3-ITD AML patients with an NGS panel of 39 genes and correlated mutational status with the length and IS of ITD. The AUC of the ROC curve of the ITD length for OS prediction was 0.504, and no differences were found when applying any of the thresholds for OS, RFS or CR rate. Only four out of 106 patients had ITD IS in the TKD1 domain. Our results, alongside previous publications, confirm that FLT3-ITD length lacks prognostic value and clinical applicability.
PB Nature Publishing Group
YR 2021
FD 2021-10-20
LK https://hdl.handle.net/10668/28337
UL https://hdl.handle.net/10668/28337
LA en
NO Castaño-Bonilla T, Alonso-Dominguez JM, Barragán E, Rodríguez-Veiga R, Sargas C, Gil C, et al. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. Sci Rep. 2021 Oct 20;11(1):20745.
DS RISalud
RD Aug 6, 2025